[
  {
    "ts": null,
    "headline": "Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%",
    "summary": "Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing",
    "url": "https://finnhub.io/api/news?id=a38286943903755f228ca509ba1f5e3fbd74300fac4ce14002d4e939161224a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770915617,
      "headline": "Kahn Brothers Reduces Stake in Pfizer Inc by 21.66%",
      "id": 139066893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing",
      "url": "https://finnhub.io/api/news?id=a38286943903755f228ca509ba1f5e3fbd74300fac4ce14002d4e939161224a9"
    }
  },
  {
    "ts": null,
    "headline": "MDGL Strengthens MASH Franchise With New Genetic Approaches",
    "summary": "Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.",
    "url": "https://finnhub.io/api/news?id=7d5b2699e90140a32af549396c2f7410754a142797e2e7afed23906bfb1f5e06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770910680,
      "headline": "MDGL Strengthens MASH Franchise With New Genetic Approaches",
      "id": 139066960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Madrigal inks $4.4B siRNA licensing deal with Ribo in $60M upfront pact, adding preclinical candidates, expanding MASH pipeline and eyeing FDA filings in 2026.",
      "url": "https://finnhub.io/api/news?id=7d5b2699e90140a32af549396c2f7410754a142797e2e7afed23906bfb1f5e06"
    }
  },
  {
    "ts": null,
    "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the “buy the rumor, sell the news” cliche came in fast and strong, quickly turning the rally into ... Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More",
    "url": "https://finnhub.io/api/news?id=0ede63b50c2e76787b8e484fe3285ed26b537f15dc263edac11f2267b6a6ec18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770901249,
      "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More",
      "id": 139056625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the “buy the rumor, sell the news” cliche came in fast and strong, quickly turning the rally into ... Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More",
      "url": "https://finnhub.io/api/news?id=0ede63b50c2e76787b8e484fe3285ed26b537f15dc263edac11f2267b6a6ec18"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook",
    "summary": "Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors. The company reported positive topline phase 2b results for its obesity drug candidate PF-3944 and plans to start multiple phase 3 trials in 2026. Both updates relate to large areas of unmet medical need in hemophilia and obesity care. For investors watching NYSE:PFE, these clinical updates arrive with the stock at $27.73 and a value score of 5. Over the past year, the...",
    "url": "https://finnhub.io/api/news?id=804eaeb179c2d4fa4efe9fcdf37d3b29f54d2ecad6147484191e7b9645ea2d12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770870633,
      "headline": "Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook",
      "id": 139052777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors. The company reported positive topline phase 2b results for its obesity drug candidate PF-3944 and plans to start multiple phase 3 trials in 2026. Both updates relate to large areas of unmet medical need in hemophilia and obesity care. For investors watching NYSE:PFE, these clinical updates arrive with the stock at $27.73 and a value score of 5. Over the past year, the...",
      "url": "https://finnhub.io/api/news?id=804eaeb179c2d4fa4efe9fcdf37d3b29f54d2ecad6147484191e7b9645ea2d12"
    }
  }
]